CSPC Pharmaceutical's (HKG:1093) Oseltamivir Phosphate for Suspension obtained drug registration approval from China's National Medical Products Administration, a Tuesday filing with the Hong Kong bourse said.
The move comes as the drug is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.
Oseltamivir phosphate is indicated for the prevention and treatment of influenza A and B.